A carregar...
Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and tacrolimus. Durvalumab may induce dermatomyositi...
Na minha lista:
| Publicado no: | Respirol Case Rep |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7985661/ https://ncbi.nlm.nih.gov/pubmed/33777398 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.736 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|